Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel in Inoperable Stage IIIB or IV NSCLC
NCT00075517Phase 2Unknown
- Sponsor
- GERCOR
- Start
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and docetaxel in non-small cell lung cancer (NSCLC), sponsored by GERCOR. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
gemcitabinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00075517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075517.